Fig. 2.
Fig. 2. Expression of selectin ligands and sLex during discontinuation and resumption of fucose therapy. / Neutrophils were isolated at the time points before (row I) and during discontinuation (rows II and III) and during resumption of therapy (rows IV and V) as indicated on the left. Expression levels were analyzed by flow cytometry, using the following reagents: (A and B) E-selectin–IgG (E-Sel–IgG) or P-selectin–IgG (P-Sel–IgG) in the presence of Ca++ (red, bold line), or in the presence of EDTA (green, thin line), VE-cadherin–IgG (blue, dashed line); (C) anti-sLex monoclonal antibody CSLEX-1 (red, bold line). In each case the fluorescence-labeled secondary antibody alone (negative control) was depicted in black (dotted line).

Expression of selectin ligands and sLex during discontinuation and resumption of fucose therapy.

Neutrophils were isolated at the time points before (row I) and during discontinuation (rows II and III) and during resumption of therapy (rows IV and V) as indicated on the left. Expression levels were analyzed by flow cytometry, using the following reagents: (A and B) E-selectin–IgG (E-Sel–IgG) or P-selectin–IgG (P-Sel–IgG) in the presence of Ca++ (red, bold line), or in the presence of EDTA (green, thin line), VE-cadherin–IgG (blue, dashed line); (C) anti-sLex monoclonal antibody CSLEX-1 (red, bold line). In each case the fluorescence-labeled secondary antibody alone (negative control) was depicted in black (dotted line).

Close Modal

or Create an Account

Close Modal
Close Modal